vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Revolve Group, Inc. (RVLV). Click either name above to swap in a different company.
Revolve Group, Inc. is the larger business by last-quarter revenue ($324.4M vs $281.3M, roughly 1.2× Guardant Health, Inc.). Revolve Group, Inc. runs the higher net margin — 5.7% vs -45.7%, a 51.4% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 10.4%). Revolve Group, Inc. produced more free cash flow last quarter ($-13.3M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 9.5%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Revolve Theatre Company is a Henley-on-Thames based theatre company specialising in political and Shakespearean plays. The company is owned by Oliver Dench, Joe Morris and Tom Smith.
GH vs RVLV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $324.4M |
| Net Profit | $-128.5M | $18.6M |
| Gross Margin | 64.6% | 53.3% |
| Operating Margin | -43.0% | 6.3% |
| Net Margin | -45.7% | 5.7% |
| Revenue YoY | 39.4% | 10.4% |
| Net Profit YoY | -15.8% | 50.4% |
| EPS (diluted) | $-1.01 | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $324.4M | ||
| Q3 25 | $265.2M | $295.6M | ||
| Q2 25 | $232.1M | $309.0M | ||
| Q1 25 | $203.5M | $296.7M | ||
| Q4 24 | $201.8M | $293.7M | ||
| Q3 24 | $191.5M | $283.1M | ||
| Q2 24 | $177.2M | $282.5M | ||
| Q1 24 | $168.5M | $270.6M |
| Q4 25 | $-128.5M | $18.6M | ||
| Q3 25 | $-92.7M | $21.2M | ||
| Q2 25 | $-99.9M | $10.2M | ||
| Q1 25 | $-95.2M | $11.8M | ||
| Q4 24 | $-111.0M | $12.3M | ||
| Q3 24 | $-107.8M | $11.0M | ||
| Q2 24 | $-102.6M | $15.4M | ||
| Q1 24 | $-115.0M | $10.9M |
| Q4 25 | 64.6% | 53.3% | ||
| Q3 25 | 64.7% | 54.6% | ||
| Q2 25 | 65.0% | 54.1% | ||
| Q1 25 | 63.3% | 52.0% | ||
| Q4 24 | 61.6% | 52.5% | ||
| Q3 24 | 61.1% | 51.2% | ||
| Q2 24 | 59.1% | 54.0% | ||
| Q1 24 | 61.2% | 52.3% |
| Q4 25 | -43.0% | 6.3% | ||
| Q3 25 | -37.3% | 7.1% | ||
| Q2 25 | -45.9% | 5.8% | ||
| Q1 25 | -54.6% | 5.0% | ||
| Q4 24 | -62.4% | 3.9% | ||
| Q3 24 | -61.3% | 5.0% | ||
| Q2 24 | -56.8% | 5.8% | ||
| Q1 24 | -59.2% | 3.4% |
| Q4 25 | -45.7% | 5.7% | ||
| Q3 25 | -35.0% | 7.2% | ||
| Q2 25 | -43.0% | 3.3% | ||
| Q1 25 | -46.8% | 4.0% | ||
| Q4 24 | -55.0% | 4.2% | ||
| Q3 24 | -56.3% | 3.9% | ||
| Q2 24 | -57.9% | 5.4% | ||
| Q1 24 | -68.2% | 4.0% |
| Q4 25 | $-1.01 | $0.27 | ||
| Q3 25 | $-0.74 | $0.29 | ||
| Q2 25 | $-0.80 | $0.14 | ||
| Q1 25 | $-0.77 | $0.16 | ||
| Q4 24 | $-0.90 | $0.18 | ||
| Q3 24 | $-0.88 | $0.15 | ||
| Q2 24 | $-0.84 | $0.21 | ||
| Q1 24 | $-0.94 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $292.3M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $512.5M |
| Total Assets | $2.0B | $765.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $292.3M | ||
| Q3 25 | $580.0M | $315.4M | ||
| Q2 25 | $629.1M | $310.7M | ||
| Q1 25 | $698.6M | $300.8M | ||
| Q4 24 | $525.5M | $256.6M | ||
| Q3 24 | $585.0M | $252.8M | ||
| Q2 24 | $933.7M | $244.7M | ||
| Q1 24 | $1.0B | $273.4M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $512.5M | ||
| Q3 25 | $-354.5M | $490.2M | ||
| Q2 25 | $-305.5M | $468.6M | ||
| Q1 25 | $-250.8M | $453.4M | ||
| Q4 24 | $-139.6M | $437.8M | ||
| Q3 24 | $-60.1M | $420.8M | ||
| Q2 24 | $-1.6M | $405.8M | ||
| Q1 24 | $68.3M | $389.9M |
| Q4 25 | $2.0B | $765.0M | ||
| Q3 25 | $1.3B | $751.3M | ||
| Q2 25 | $1.3B | $722.9M | ||
| Q1 25 | $1.3B | $713.9M | ||
| Q4 24 | $1.5B | $665.5M | ||
| Q3 24 | $1.5B | $670.9M | ||
| Q2 24 | $1.6B | $657.8M | ||
| Q1 24 | $1.7B | $650.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-10.2M |
| Free Cash FlowOCF − Capex | $-54.2M | $-13.3M |
| FCF MarginFCF / Revenue | -19.3% | -4.1% |
| Capex IntensityCapex / Revenue | 9.9% | 1.0% |
| Cash ConversionOCF / Net Profit | — | -0.55× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $48.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $-10.2M | ||
| Q3 25 | $-35.4M | $11.8M | ||
| Q2 25 | $-60.3M | $12.6M | ||
| Q1 25 | $-62.7M | $45.1M | ||
| Q4 24 | $-64.5M | $3.9M | ||
| Q3 24 | $-51.1M | $9.1M | ||
| Q2 24 | $-94.0M | $-24.7M | ||
| Q1 24 | $-30.3M | $38.4M |
| Q4 25 | $-54.2M | $-13.3M | ||
| Q3 25 | $-45.8M | $7.5M | ||
| Q2 25 | $-65.9M | $10.4M | ||
| Q1 25 | $-67.1M | $43.4M | ||
| Q4 24 | $-83.4M | $2.1M | ||
| Q3 24 | $-55.3M | $8.0M | ||
| Q2 24 | $-99.1M | $-25.7M | ||
| Q1 24 | $-37.2M | $36.7M |
| Q4 25 | -19.3% | -4.1% | ||
| Q3 25 | -17.3% | 2.5% | ||
| Q2 25 | -28.4% | 3.4% | ||
| Q1 25 | -33.0% | 14.6% | ||
| Q4 24 | -41.3% | 0.7% | ||
| Q3 24 | -28.9% | 2.8% | ||
| Q2 24 | -55.9% | -9.1% | ||
| Q1 24 | -22.1% | 13.5% |
| Q4 25 | 9.9% | 1.0% | ||
| Q3 25 | 3.9% | 1.5% | ||
| Q2 25 | 2.4% | 0.7% | ||
| Q1 25 | 2.2% | 0.6% | ||
| Q4 24 | 9.4% | 0.6% | ||
| Q3 24 | 2.2% | 0.4% | ||
| Q2 24 | 2.9% | 0.4% | ||
| Q1 24 | 4.1% | 0.6% |
| Q4 25 | — | -0.55× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.83× | ||
| Q2 24 | — | -1.60× | ||
| Q1 24 | — | 3.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
